Lafutidine versus Lansoprazole in Combination with Clarithromycin and Amoxicillin for One versus Two Weeks for Helicobacter pylori Eradication in Korea
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2
- 저널
- HELICOBACTER13(6) · pp.542 · 2008
- 피인용
- Web of Science 17
- JCR IF
- JCR 2007 2.423
- ISSN
- 1083-4389
저자
- Kim, Nayoung제1저자서울대학교, Dept Internal Med, KO
- Park, Soo-Heon가톨릭대학교, Dept Internal Med, KO
- Seo, Geom원광대학교, Dept Internal Med, KO
- Lee, Sang Woo고려대학교, Dept Internal Med, KO
- Kim, Jae Woo연세대학교, Wonju Coll Med, Dept Internal Med, KO
- Lee, Kwang Jae아주대학교, Dept Gastroenterol, KO
- Shin, Won-Chang인제대학교, Sanggye Paik Hosp, Dept Internal Med, KO
- Kim, Tae Nyeun영남대학교, Dept Internal Med, KO
- Park, Moo-In고신대학교, Gospel Hosp, Dept Internal Med, KO
- Park, Jong-Jae고려대학교, Dept Internal Med, KO
- Hong, Su Jin순천향대학교, Dept Internal Med, KO
- Shim, Ki-Nam이화여자대학교, Sch Med, Dept Internal Med, KO
- Kim, Sang Wook전북대학교, Dept Internal Med, KO
- Shin, Yong-Woon인하대학교, Dept Internal Med, KO
- Chang, Young-Woon경희대학교, Dept Internal Med, KO
- Chun, Hoon Jai고려대학교, Dept Internal Med, KO
- Lee, Ok-Jae경상대학교, Dept Internal Med, KO
- Jeon, Won-Joong충북대학교, Dept Internal Med, KO
- Park, Chan-Guk조선대학교, Dept Internal Med, KO
- Cho, Chang-Min경북대학교, Dept Internal Med, KO
- Park, Cheol Hee한림대학교, Dept Internal Med, KO
- Won, Sun Young국민건강보험공단, Natl Hlth Insurance Corp, Dept Internal Med, KO
- Lee, Gin Hyug울산대학교, Dept Internal Med, KO
- Park, Kyung Sik계명대학교, Dept Internal Med, KO
- Shin, Jeong Eun단국대학교, Dept Internal Med, KO
- Kim, Heung Up제주대학교, Dept Internal Med, KO
- Park, Joon Yong한림대학교, Dept Internal Med, KO
- Chae, Hiun Suk가톨릭대학교, Dept Internal Med, KO
- 송근암부산대학교, 의과대학, 의학과, KO
- Kim, Jae Gyu중앙대학교, Dept Internal Med, KO
초록
Lafutidine is a novel H-2-receptor antagonist with gastroprotective activity that includes enhancement of gastric mucosal blood flow. The aim of the present study was to test the efficacy of 7- or 14-day lafutidine-clarithromycin-amoxicillin therapy versus a lansoprazole-based regimen for Helicobacter pylori eradication. Four hundred and sixty-three patients with H. pylori-infected peptic ulcer disease were randomized to one of four regimens: (1) lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.) and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LFT group) or (2) for 14 days (the 14LFT group); (3) lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LPZ group); or (4) for 14 days (the 14LPZ group). The eradication rates, drug compliance, and adverse effects among the four regimens were compared. The eradication rates by the intention-to-treat and per-protocol analyses in the 7LFT and 7LPZ groups were 76.5% and 81.6%, and 76.9% and 82.0% (p = .94 and .95), respectively. The eradication rates by intention-to-treat and per-protocol analyses in the 14LFT and 14LPZ groups were 78.2% and 82.2%, and 80.4% and 85.9% (p = .70 and .49), respectively. The treatment duration for 7 days or 14 days did not affect the eradication rates. In addition, the adverse effect rates and discontinuation rates were similar among the four groups. Furthermore, the ulcer cure rate and symptom response rate were similar in the lafutidine and lansoprazole groups. The results of this study showed that lafutidine-clarithromycin-amoxicillin therapy was a safe and effective as lansoprazole-based triple therapy for the eradication rate of H. pylori, and could be considered as an additional treatment option.
식별자
- WoS UID
- 000260823300008



로그인
연구물 목록으로